Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.
Paola SimeoneRomina TripaldiAnnika MichelsenThor UelandRossella LianiSonia CiottiKåre I BirkelandHanne L GulsethAugusto Di CastelnuovoFrancesco CipollonePål AukrustAgostino ConsoliBente HalvorsenFrancesca SantilliPublished in: Cardiovascular diabetology (2022)
Liraglutide-induced reduction in sST2 and possibly hs-TnI suggests that in obese patients with prediabetes or early T2DM this drug may have a positive effect on (cardiac) fibrosis, whereas plasma level of Gal-3 before liraglutide initiation may predict response to the drug in terms of beta cell function improvement. Trial registration Eudract: 2013-001356-36.
Keyphrases
- weight loss
- glycemic control
- type diabetes
- bariatric surgery
- roux en y gastric bypass
- gastric bypass
- drug induced
- metabolic syndrome
- adipose tissue
- obese patients
- clinical trial
- cardiovascular disease
- study protocol
- high glucose
- adverse drug
- diabetic rats
- left ventricular
- phase iii
- weight gain
- randomized controlled trial
- insulin resistance
- phase ii
- physical activity
- endothelial cells
- atrial fibrillation